NEW YORK, June 29 (GenomeWeb News) - Proteome Sciences licensed its stroke biomarkers to "one of the top 10 global leaders in clinical diagnostics," the company said yesterday.
Under the research license, a number of Proteome Sciences biomarkers will be tested inclusion in a new panel for a high-throughput diagnostic platform. After incorporating the stroke markers, the licensee will develop an HTS stroke test, Proteome Sciences said in a statement.
The licensee declined to be identified by Proteome Sciences, citing competitive reasons. Proteome Sciences did say this is a new area for the licensee.
No financial details were disclosed.